Przejdź do zawartości
Merck

Enhanced bacterial tumor delivery by modulating the EPR effect and therapeutic potential of Lactobacillus casei.

Journal of pharmaceutical sciences (2014-07-22)
Jun Fang, Long Liao, Hongzhuan Yin, Hideaki Nakamura, Takashi Shin, Hiroshi Maeda
ABSTRAKT

Bacteria of micrometer size could accumulate in tumor based on enhanced permeability and retention (EPR) effect. We report here Lactobacillus casei (L. casei), a nonpathogenic facultatively anaerobic bacterium, preferentially accumulated in tumor tissues after intravenously (i.v.) injection; at 24 h, live bacteria were found more in the tumor, whereas the bacteria in normal tissues including the liver and spleen were cleared rapidly. The tumor-selective accumulation and growth of L. casei is probably due to the EPR effect and the hypoxic tumor environment. Moreover, the bacterial tumor delivery was significantly increased by a nitric oxide (NO) donor nitroglycerin (NG, 10-70 times) and an angiotensin II converting enzyme inhibitor, enalapril (6-18 times). Consequently significant suppression of tumor growth was found in a colon cancer C26 model, and more remarkable antitumor effect was achieved when L. casei was combined with NG, probably by modulating the host nonspecific immune responses; tumor necrosis factor-α significantly increased in tumor after the treatment, as well as NO synthase activity and myleoperoxidase activity. These findings suggest the potential of L. casei as a candidate for targeted bacterial antitumor therapy, especially in combine with NG or other vascular mediators.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
Lactulose, ≥98.0% (HPLC)
Sigma-Aldrich
Lactulose, ≥95% (HPLC)
Lactulose, European Pharmacopoeia (EP) Reference Standard
Supelco
Lactulose, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Lactulose, United States Pharmacopeia (USP) Reference Standard